Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01954017 · ClinicalTrials.gov registry record · Phase 1
STP206 for the Prevention of Necrotizing Enterocolitis (NEC)
A Phase 1 study, sponsored by Leadiant Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
NCT01954017 is a Phase 1 study that has completed, run by Leadiant Biosciences. The registered enrollment target is 103 participants.
The verdict
NCT01954017, a Phase 1 study, has completed, sponsored by Leadiant Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
Study Summary
This study is a sequential dose escalation study to assess the safety, tolerability, and preliminary NEC-preventative efficacy of two doses of STP206 versus control in very low birth weight and extremely low birth weight neonates.
Interventions
- OTHER Control
- BIOLOGICAL STP206
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2014-01-30 |
| Est. Completion | 2018-10-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01954017
The ClinicalTrials.gov registry entry for NCT01954017 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Leadiant Biosciences, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.
NCT01954017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01954017 about?
NCT01954017 is a clinical study titled "STP206 for the Prevention of Necrotizing Enterocolitis (NEC)". This study is a sequential dose escalation study to assess the safety, tolerability, and preliminary NEC-preventative efficacy of two doses of STP206 versus control in very low birth weight and extremely low birth weight neonates.
What is the current status of trial NCT01954017?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2014-01-30. Estimated completion is 2018-10-22.
What interventions are being tested in trial NCT01954017?
The interventions under investigation include: Control (OTHER), STP206 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01954017?
This trial is sponsored by Leadiant Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.